Michael John Tomsicek - Aug 6, 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Financial Officer
Signature
/s/ Michael Esposito, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Aug 6, 2021
Transactions value $
-$3,019,176
Form type
4
Date filed
8/10/2021, 08:00 PM
Previous filing
Jul 29, 2021
Next filing
Aug 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $444K +25K +1322.05% $17.75 26.9K Aug 6, 2021 Direct
transaction CRSP Common Shares Sale -$2.63M -19K -70.7% $138.22 7.88K Aug 6, 2021 Direct F1, F2
transaction CRSP Common Shares Sale -$835K -5.99K -76% $139.46 1.89K Aug 6, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -25K -16.03% $0.00 131K Mar 11, 2021 Common Shares 25K $17.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.